News

As early as September 17, we can expect a reimbursement announcement that will be important for the field of hemato-oncology. At the “Healthcare Policy Roundtable – Hemato-Oncology” meeting on rare diseases, organized last Friday by the Institute for Social Development, Mateusz Oczkowski, Deputy Director of the Department of Drug Policy and Pharmacy at the Ministry of Health, revealed that the announcement will include six new indications, likely:

👉 Two new CAR-T therapies
👉 Three bispecific antibodies

“I don’t remember a reimbursement announcement packed with such a high level of technology,” summarized Mateusz Oczkowski. At the same meeting, Prof. Ewa Lech-Marańda, National Consultant in Hematology, stated that between 2019 and 2023, 75 new molecule-indications were reimbursed across 26 hematologic cancers and non-cancerous diseases. Mateusz Oczkowski commented that in 2024, the number of similar decisions will definitely exceed 90!